Literature DB >> 10582905

Comparative bacteriostatic and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato.

R Murgia1, F Marchetti, M Cinco.   

Abstract

The MIC and MSC (minimum spirocheticidal concentration) and killing rate for Borrelia burgdorferi, the etiological agent of Lyme disease, were assessed for cefodizime in comparison with ceftriaxone, minocycline, azithromycin, roxithromycin, and ciprofloxacin. The range of cefodizime MICs was greater than those of azithromycin and roxithromycin but comparable to those of ceftriaxone and minocycline. The MSCs were 1 to 2 dilutions higher than the MICs of all of the tested compounds. The killing curves of cefodizime and ceftriaxone showed parallel courses. In conclusion, cefodizime exerted an activity comparable to that of ceftriaxone against B. burgdorferi.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10582905      PMCID： PMC89610          DOI： 10.1128/AAC.43.12.3030

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  [Borrelia burgdorferi infection. I. Aspects of basic research, current approach for diagnosis and therapy].

Authors:  M D Kramer; R Wallich; U E Schaible; G Zimmer; M M Simon
Journal:  Hautarzt       Date:  1990-12       Impact factor: 0.751

2.  Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.

Authors:  R C Johnson; C B Kodner; P J Jurkovich; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 3.  The in-vitro activity of cefodizime: a review.

Authors:  C J Soussy; M Chanal; M D Kitzis
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

4.  Isolation of Borrelia burgdorferi from myocardium.

Authors:  G Lardieri; A Salvi; F Camerini; M Cińco; G Trevisan
Journal:  Lancet       Date:  1993-08-21       Impact factor: 79.321

5.  Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis.

Authors:  V Preac-Mursic; K Weber; H W Pfister; B Wilske; B Gross; A Baumann; J Prokop
Journal:  Infection       Date:  1989 Nov-Dec       Impact factor: 3.553

6.  Use of polymerase chain reaction and specific monoclonal antibodies as rapid method to recognize Borrelia burgdorferi sensu stricto, B. garinii and B. afzelii among Italian isolates of B. burgdorferi.

Authors:  M Cinco; C Costantini; B Wilske; G Graziosi; G Trevisan; F Florian
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

7.  In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.

Authors:  J M Levin; J A Nelson; J Segreti; B Harrison; C A Benson; F Strle
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

8.  In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.

Authors:  R C Johnson; C Kodner; M Russell
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

9.  Diversity of Borrelia burgdorferi sensu lato evidenced by restriction fragment length polymorphism of rrf (5S)-rrl (23S) intergenic spacer amplicons.

Authors:  D Postic; M V Assous; P A Grimont; G Baranton
Journal:  Int J Syst Bacteriol       Date:  1994-10

10.  In vitro activity of rokitamycin, a new macrolide, against Borrelia burgdorferi.

Authors:  M Cinco; D Padovan; G Stinco; G Trevisan
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191
View more
  5 in total

1.  In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi.

Authors:  P Kraiczy; J Weigand; T A Wichelhaus; P Heisig; H Backes; V Schäfer; G Acker; V Brade; K P Hunfeld
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

2.  Generality of Post-Antimicrobial Treatment Persistence of Borrelia burgdorferi Strains N40 and B31 in Genetically Susceptible and Resistant Mouse Strains.

Authors:  Emir Hodzic; Denise M Imai; Edlin Escobar
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

Review 3.  Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.

Authors:  Klaus-Peter Hunfeld; Volker Brade
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

4.  Persistence of Borrelia burgdorferi following antibiotic treatment in mice.

Authors:  Emir Hodzic; Sunlian Feng; Kevin Holden; Kimberly J Freet; Stephen W Barthold
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

Review 5.  Borreliella burgdorferi Antimicrobial-Tolerant Persistence in Lyme Disease and Posttreatment Lyme Disease Syndromes.

Authors:  Felipe C Cabello; Monica E Embers; Stuart A Newman; Henry P Godfrey
Journal:  mBio       Date:  2022-04-25       Impact factor: 7.786
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.